Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Physiomics ( (GB:PYC) ).
Physiomics plc, a mathematical modelling and data science consultancy serving the biopharmaceutical sector, has secured a new contract with long-standing client Numab Therapeutics AG. The engagement centres on applying model-informed drug development techniques to support early-stage oncology decision-making, further entrenching Physiomics’ role in complex therapeutics development.
Under the agreement, Physiomics will build a mechanistic pharmacokinetic-pharmacodynamic framework to back proof-of-concept activities for a new oncology programme in Numab’s pipeline. The project, running from April to the third quarter of 2026, will use quantitative analysis to interpret emerging data, refine experimental design and inform go/no-go decisions, strengthening the collaboration and underscoring the growing adoption of modelling approaches in oncology R&D portfolios.
Spark’s Take on PYC Stock
According to Spark, TipRanks’ AI Analyst, PYC is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and persistent cash burn), partially offset by a low-leverage balance sheet and some improvement in price trend. Valuation is constrained by negative earnings and lack of dividend support.
To see Spark’s full report on PYC stock, click here.
More about Physiomics
Physiomics plc is a UK-based specialist in mathematical modelling, data science, biostatistics and bioinformatics for the biotech and pharma industry. The company uses computational tools, bespoke models and its proprietary Virtual Tumour technology to help clients streamline drug development, de-risk decision-making and optimise study design across discovery, pre-clinical and clinical stages. Its client base includes major pharma and innovative biotechs such as Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics and Cancer Research UK.
Average Trading Volume: 8,252,992
Technical Sentiment Signal: Sell
Current Market Cap: £2.15M
See more insights into PYC stock on TipRanks’ Stock Analysis page.